TherapeuticsMD Inc
NASDAQ:TXMD
TherapeuticsMD Inc
NASDAQ:TXMD
Price:
1.96 USD
Updated:
May 8, 2024
TherapeuticsMD Inc
Cash from Financing Activities
|
TherapeuticsMD Inc
Cash from Financing Activities Peer Comparison
Comparables:
JNJ
BMY
PFE
MRK
LLY
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
TherapeuticsMD Inc
NASDAQ:TXMD
|
Cash from Financing Activities
$3.2m
|
CAGR 3-Years
-66%
|
CAGR 5-Years
-55%
|
CAGR 10-Years
-27%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Cash from Financing Activities
-$21.4B
|
CAGR 3-Years
-46%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-10%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cash from Financing Activities
$8.3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Pfizer Inc
NYSE:PFE
|
Cash from Financing Activities
$26.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Merck & Co Inc
NYSE:MRK
|
Cash from Financing Activities
-$5.6B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
14%
|
CAGR 10-Years
-7%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Cash from Financing Activities
$2.8B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is TherapeuticsMD Inc's Cash from Financing Activities?
Cash from Financing Activities
3.2m
USD
3.2m
USD
Based on the financial report for Dec 31, 2023, TherapeuticsMD Inc's Cash from Financing Activities amounts to 3.2m USD.
What is TherapeuticsMD Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
-27%
-27%
The average annual Cash from Financing Activities growth rates for TherapeuticsMD Inc have been -66% over the past three years , -55% over the past five years , and -27% over the past ten years .
You don't have any saved screeners yet
